Skip to content
Home/Companies/Biotech/Verona Pharma
VP

Verona Pharma

Biotech·UK·Exited 2025·Held 6yr

Verona Pharma is a healthcare company, headquartered in United Kingdom.

Entry
2019
Hold
6yr
Exit
2025
Est. EV
–

Who owns Verona Pharma?

Verona Pharma was owned by Sofinnova Partners through Sofinnova Crossover Fund I (2018 vintage) from 2019 to 2025, exited via Trade Sale. Across its history, Verona Pharma has been through 2 private equity ownership periods, detailed in the timeline below.

Buyer identity available on Pro.

Hand-verified · updated 2026-04-21

Sofinnova Partners
Most recent investor
Sofinnova Partners
Sofinnova Crossover Fund I · 2018 · VC
2 ownership periods · full history below

Key facts

HQUnited Kingdom
SectorHealthcare
Key takeaways
  • ·Fully exited in 2025.
  • ·Average hold across 2 realized cycles: 4 years.

Ownership history

2 ownership periods

Exited
Last exited in 2025 to .
Andera Partners
Andera PartnersExited 2017
2016 · 2017 · BioDiscovery 4 · 2013 · VC
Trade Sale
MOIC
–
Sofinnova Partners
Sofinnova PartnersExited 2025
2019 · 2025 · Sofinnova Crossover Fund I · 2018 · VC
Trade Sale · to
MOIC
–

More from Sofinnova Crossover Fund I

Other portfolio companies in the same fund.

GenSight Biologics
Active
BiotechFrance
Amolyt Pharma
Exited 2024
BiotechFrance· 2021
to
Sphere Bio (formerly Sphere Fluidics)
Exited 2025
MedTechUnited Kingdom· 2021
to
Artios Pharma
Active
BiotechUK· 2020
Calliditas
Exited 2024
BiotechSweden· 2020
to
Hemab Therapeutics
Active
BiotechDenmark· 2020

More PE-backed in Biotech

Comparable biotech deals from other GPs.

InBrain Pharma
Active
Finovam GestionFrance
Isavy Biotech
Active
Ring CapitalFrance
NeoVacs
Active
Odyssée VentureFrance
ReNeuron Group
Exited 2024
Obotritia CapitalUnited Kingdom
Univercells
Exited 2023
AdBio PartnersBelgium
to
2NA FISH
Active
Gruenderfonds RuhrGermany· 2026
Data refreshed weekly · Sourced from public filings